HTMC0658
Phase 2Small molecule
HTMC0658 is one of 10 small molecule programs targeting Chronic Rhinosinusitis Without Nasal Polyps. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Chronic Rhinosinusitis Without Nasal Polyps
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Approved
Asmanex Hfa
PPerrigo Company
Approved
Flovent
GSKPhase 3
Asmanex
NovartisPhase 2
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Brinsupri
IInsmed Incorporated
Phase 2
Itepekimab AI
SanofiPhase 2
OPN-375
OOptinose US Inc.
Phase 3
Augmentin
TevaPreclinical
HTMC0658
SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HTMC0658. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details